Sees Q4 revenue $397M-$403M, consensus $405.48M. This represents a growth of -0.4% to +1.1% and organic growth of -0.8% to +0.7%. Adjusted EPS view include the impact of the Boston recall, the strength of the U.S. dollar, and an updated tax rate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Third Quarter 2023 Financial Results
- IART Upcoming Earnings Report: What to Expect?
- Integra LifeSciences price target lowered to $41 from $48 at Truist
- Integra LifeSciences to Host Third Quarter 2023 Financial Results Conference Call on October 25, 2023
- Integra LifeSciences to Present at the 2023 Wells Fargo Healthcare Conference
